BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30944645)

  • 1. Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma.
    Hwang C; Lee SJ; Lee JH; Kim KH; Suh DS; Kwon BS; Choi KU
    Oncol Lett; 2019 May; 17(5):4557-4565. PubMed ID: 30944645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma.
    Hwang C; Lee HJ; Na JY; Kim KH; Song YJ; Kim JY; Kim K; Shin DH; Park JY; Kim SY; Lee JH; Choi KU
    J Ovarian Res; 2023 Jan; 16(1):3. PubMed ID: 36609273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer.
    James FR; Jiminez-Linan M; Alsop J; Mack M; Song H; Brenton JD; Pharoah PDP; Ali HR
    BMC Cancer; 2017 Sep; 17(1):657. PubMed ID: 28931370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage.
    Pujani M; Jain H; Chauhan V; Agarwal C; Singh K; Singh M
    Breast Dis; 2020; 39(2):61-69. PubMed ID: 32310155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer.
    Rakaee M; Kilvaer TK; Dalen SM; Richardsen E; Paulsen EE; Hald SM; Al-Saad S; Andersen S; Donnem T; Bremnes RM; Busund LT
    Hum Pathol; 2018 Sep; 79():188-198. PubMed ID: 29885403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer.
    Ölmez F; Oğlak SC; Ölmez ÖF; Akbayır Ö; Yılmaz E; Akgöl S; Konal M; Seyhan NA; Kinter AK
    Turk J Obstet Gynecol; 2022 Sep; 19(3):246-256. PubMed ID: 36149309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating tumor-infiltrating lymphocytes in hepatocellular carcinoma using hematoxylin and eosin-stained tumor sections.
    Du M; Cai YM; Yin YL; Xiao L; Ji Y
    World J Clin Cases; 2022 Jan; 10(3):856-869. PubMed ID: 35127901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Deep Learning-Based Assessment Pipeline for Intraepithelial and Stromal Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Carcinoma.
    Hamada K; Murakami R; Ueda A; Kashima Y; Miyagawa C; Taki M; Yamanoi K; Yamaguchi K; Hamanishi J; Minamiguchi S; Matsumura N; Mandai M
    Am J Pathol; 2024 Jul; 194(7):1272-1284. PubMed ID: 38537936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
    Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C
    J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer.
    Wu J; Li X; Teng X; Rubin DL; Napel S; Daniel BL; Li R
    Breast Cancer Res; 2018 Sep; 20(1):101. PubMed ID: 30176944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
    Tomsová M; Melichar B; Sedláková I; Steiner I
    Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial).
    Googe PB; Theocharis S; Pergaris A; Li H; Yan Y; McKenna EF; Moschos SJ
    Curr Probl Cancer; 2022 Jun; 46(3):100862. PubMed ID: 35398635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma.
    Choi KU; Kim A; Kim JY; Kim KH; Hwang C; Lee SJ; Park WY; Jung S; Choi HJ; Kim K
    J Ovarian Res; 2020 Jun; 13(1):65. PubMed ID: 32513298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.
    Miglietta F; Ragazzi M; Fernandes B; Griguolo G; Massa D; Girardi F; Bottosso M; Bisagni A; Zarrilli G; Porra F; Iannaccone D; Dore L; Gaudio M; Santandrea G; Fassan M; Lo Mele M; De Sanctis R; Zambelli A; Bisagni G; Guarneri V; Dieci MV
    Clin Cancer Res; 2023 Sep; 29(17):3429-3437. PubMed ID: 37417941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections.
    Iseki Y; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Matsutani S; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
    PLoS One; 2018; 13(4):e0192744. PubMed ID: 29698402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer.
    Ahn S; Chung YR; Seo AN; Kim M; Woo JW; Park SY
    PLoS One; 2020; 15(5):e0233037. PubMed ID: 32401825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of tumor infiltrating lymphocytes in high-grade serous ovarian carcinoma].
    Huang XM; Zhang Y; Xu L; Wang M; Wang W
    Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):610-614. PubMed ID: 31422591
    [No Abstract]   [Full Text] [Related]  

  • 20. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.
    Swisher SK; Wu Y; Castaneda CA; Lyons GR; Yang F; Tapia C; Wang X; Casavilca SA; Bassett R; Castillo M; Sahin A; Mittendorf EA
    Ann Surg Oncol; 2016 Jul; 23(7):2242-8. PubMed ID: 26965699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.